Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00904475 · ClinicalTrials.gov registry record · Phase 4

Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain

A Phase 4 study of Chronic Low Back Pain, sponsored by Endo Pharmaceuticals.

Completed
Registry status
Phase 4
Development phase
102
Enrollment target
6
Study locations

NCT00904475 is a Phase 4 study of Chronic Low Back Pain that has completed, run by Endo Pharmaceuticals. The registered enrollment target is 102 participants, below the 591-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (83% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00904475, a Phase 4 study of Chronic Low Back Pain, has completed, sponsored by Endo Pharmaceuticals.

COMPLETED
Registry status
Phase 4
Development phase
102 participants
Enrollment target
6
Study locations

Study Summary

Patients with moderate to severe chronic Low Back Pain (LBP) despite current analgesic treatment participated in a Phase IV clinical trial to evaluate the analgesic efficacy of the lidocaine patch 5% compared to placebo in treating moderate to severe chronic LBP.

Conditions Studied

Interventions

  • DRUG Lidoderm®

Study Locations (6)

Alabama

  • - Birmingham
  • - Hueytown

Arizona

  • - Phoenix

California

  • - Mill Valley

Pennsylvania

  • - Allentown

Utah

  • - Salt Lake City

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2003-04
Phase Phase 4

Sponsor

Endo Pharmaceuticals

23 total trials

What the Registry Record Tells You About NCT00904475

The ClinicalTrials.gov registry entry for NCT00904475 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 591-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (83% lower). The listed sponsor is Endo Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Low Back Pain appearing as the primary indexed condition, and to 1 intervention - of which Lidoderm® is the first listed.

NCT00904475 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Alabama, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT00904475 about?

NCT00904475 is a clinical study titled "Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain". Patients with moderate to severe chronic Low Back Pain (LBP) despite current analgesic treatment participated in a Phase IV clinical trial to evaluate the analgesic efficacy of the lidocaine patch 5% compared to placebo in treating moderate to severe chronic LBP.

What is the current status of trial NCT00904475?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 102 participants. The study started on 2003-04.

What conditions does trial NCT00904475 study?

This clinical trial studies the following conditions: Chronic Low Back Pain.

What interventions are being tested in trial NCT00904475?

The interventions under investigation include: Lidoderm® (DRUG).

Who is sponsoring clinical trial NCT00904475?

This trial is sponsored by Endo Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00904475 being conducted?

This trial has 6 study locations across Alabama, Arizona, California, Pennsylvania, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Low Back Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.